Mural Oncology plc (MURA) - Total Assets
Based on the latest financial reports, Mural Oncology plc (MURA) holds total assets worth $65.76 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore MURA debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Mural Oncology plc - Total Assets Trend (2021–2024)
This chart illustrates how Mural Oncology plc's total assets have evolved over time, based on quarterly financial data. See Mural Oncology plc book value and equity for net asset value and shareholders' equity analysis.
Mural Oncology plc - Asset Composition Analysis
Current Asset Composition (December 2024)
Mural Oncology plc's total assets of $65.76 Million consist of 90.3% current assets and 9.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 68.2% |
| Accounts Receivable | $51.00K | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Mural Oncology plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Mural Oncology plc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mural Oncology plc's current assets represent 90.3% of total assets in 2024, an increase from 12.1% in 2021.
- Cash Position: Cash and equivalents constituted 68.2% of total assets in 2024, up from -72.1% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 0.0% of total assets.
Mural Oncology plc Competitors by Total Assets
Key competitors of Mural Oncology plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
Mural Oncology plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.90 | 7.38 | 0.12 |
| Quick Ratio | 5.90 | 7.38 | 0.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $51.63 Million | $158.88 Million | $-36.74 Million |
Mural Oncology plc - Advanced Valuation Insights
This section examines the relationship between Mural Oncology plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.64 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | -43.9% |
| Total Assets | $169.39 Million |
| Market Capitalization | $35.38 Million USD |
Valuation Analysis
Below Book Valuation: The market values Mural Oncology plc's assets below their book value (0.21x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Mural Oncology plc's assets decreased by 43.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Mural Oncology plc (2021–2024)
The table below shows the annual total assets of Mural Oncology plc from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $169.39 Million | -43.86% |
| 2023-12-31 | $301.75 Million | +794.06% |
| 2022-12-31 | $33.75 Million | -3.87% |
| 2021-12-31 | $35.11 Million | -- |
About Mural Oncology plc
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cut… Read more